Sipa1 deficiency unleashes a host-immune mechanism eradicating chronic myelogenous leukemia-initiating cells
Chronic myelogenous leukemia (CML)-initiating cells are resistant to kinase inhibitors. Here the authors show that deficiency of the Rap1 GTPase-activating protein Sipa1 in the tumor microenvironment releases an immune response that eradicates CML-initiating cells via interplay between stromal and T...
Guardado en:
Autores principales: | Yan Xu, Satoshi Ikeda, Kentaro Sumida, Ryusuke Yamamoto, Hiroki Tanaka, Nagahiro Minato |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5257dd023ec6425cad3f0923e8fae487 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Bosutinib in the management of chronic myelogenous leukemia
por: Keller-von Amsberg G, et al.
Publicado: (2013) -
Spotlight on nilotinib in the treatment of chronic myelogenous leukemia
por: Harnicar S, et al.
Publicado: (2014) -
Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia
por: Judith E Karp, et al.
Publicado: (2008) -
Dynamics and potential impact of the immune response to chronic myelogenous leukemia.
por: Peter S Kim, et al.
Publicado: (2008) -
Isolation of Mycobacterium branderi, an unusual species from an acute myelogenous leukemia patient
por: Majid Marjani, et al.
Publicado: (2014)